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Kymes S1, Peters CM1, Beusterien K2, Kotak S3, Grinspan J2, Stwalley D4, Pleil A5
1Washington University School of Medicine, St. Louis, MO, USA, 2Oxford Outcomes Ltd.,
Bethesda, MD, USA, 3Pfizer, Inc., New York, NY, USA, 4Washington University, St. Louis, MO,
USA, 5Pfizer, Inc., San Diego, CA, USA
OBJECTIVES:We used multi-attribute theory to develop a utility elicitation instru-
ment for people with glaucoma based on the National Eye Institute-Visual Func-
tioning Questionnaire (NEI-VFQ), a vision specific quality of life instrument fre-
quently used in clinical trials. METHODS: NEI-VFQ responses for 1677 people
enrolled in glaucoma prevention trials were analyzed to identify items responsive
to differences in vision status. We then constructed a conjoint interview adminis-
tered to 48 people with glaucoma and identified the 6 items of greatest importance
to people with glaucoma. Using these results, we constructed a web-based inter-
view using standard gamble (SG) and visual analog scales(VAS) administered to a
community sample of 404 people. RESULTS: The five attributes most important to
people with glaucoma (and responsive to change in disease status) were: ability to
read, driving at night, ability to leave home, needing help with activities and ability
to accomplish tasks. We added a sixth attribute, peripheral vision, even though it
was not rated highly by the participants as this is an important function lost early
in the disease process. Final utility estimates weremade using amethod similar to
that employed in the Health Utility Index. The results had excellent face validity
and we note the range of utility loss frommild loss of function to severe difficulty:
1) Ability to read (0.011-0.039); 2) Driving at night (0.011-0.037); 3) Leaving home
(0.014-0.056); 4) Needing help with activities (0.027-0.063); 5) Ability to accomplish
tasks (0.016-0.046); and 6) Peripheral vision (0.008-0.032). CONCLUSIONS:We have
developed an instrument that can be used to estimate the utility loss in peoplewith
glaucomabasedupon theNEI-VFQ.Whenused in clinical trials, the instrumentwill
provide an estimate of the utility loss associatedwith the progression of glaucoma.
Further work will be required to refine and validate these estimates.
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DEVELOPMENT OF A DISEASE SPECIFIC VERSION OF THE EQ-5D FOR USE IN
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OBJECTIVES: The EQ-5D is a widely used generic measure of health. Previous re-
search has highlighted possible shortcomings in content validity in certain condi-
tions (e.g. vision, hearing loss). The objective of this study was to determine if this
was true for people with psoriasis and to address this through the development of
a disease-specific version of the EQ-5D for use in psoriasis.METHODS: A literature
review, consultationwithmedical experts and in-depth qualitative interviewswith
psoriasis patients with varying degrees of disease severity (n8) were undertaken
to understand the quality-of-life burden associated with psoriasis. An iterative
process identified four new candidate dimensions (skin irritation, skin appearance,
self-confidence and social/relationship difficulties). Thesewere included alongside
the existing five dimensions of EQ-5D. In a validation study 100 psoriasis patients
completed the new version of EQ-5D; the Dermatology Life Quality Index (DLQI)
and Self-Administered Psoriasis Area Severity Index (SAPASI). RESULTS: Psycho-
metric analyses suggested that all candidate dimensions were sensitive to disease
severity and had excellent concurrent validity. The new dimensions significantly
improved the predictive power of EQ-5D inmeasuring health status as assessed by
the DLQI with an R2 increase of 0.213 when three candidate dimensions were
added. Almost 20% of patients indicated no problems on each dimension of con-
ventional EQ-5D (state 11111), but reported substantial impairments on the psori-
asis dimensions, indicating the limitations of existing EQ-5D in psoriasis.
CONCLUSIONS: This study is part of larger research at the EuroQol Group to inves-
tigate the potential development of disease specific versions of EQ-5D. The study
demonstrates that in certain disease areas there is need for more a specific mea-
sure. The addition of appropriate dimensions can significantly increase the sensi-
tivity of the instrument. Further work is needed to capture preference weights for
this new instrument to support its inclusion in economic evaluation.
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THE EFFECT OF ORAL CP-690,550 ON PRURITUS IN PATIENTS WITH
MODERATE-TO-SEVERE PLAQUE PSORIASIS
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OBJECTIVES: To assess the effect of the oral Janus kinase inhibitor CP-690,550 on
pruritus in patientswith psoriasis.METHODS: In a 12-week, double-blind, placebo-
controlled Phase 2b study, patients (n197) with moderate-to-severe plaque pso-
riasis were randomized to CP-690,550 (2, 5 or 15 mg BID) or placebo. Pruritus was
patient-assessed using the Itch Severity Score (ISS), a 0 (‘no itching’) to 10 (‘worst
possible itching’) numeric rating scale, recorded daily during the first 2 weeks of
treatment and at all clinic visits. The clinically important difference (CID) and
clinically important responder (CIR) on the ISS were defined using the Patient
Global Assessment as an anchor. RESULTS: At Baseline, mean (SD) ISS for patients
in the 2, 5, and 15mg BID and placebo groups were 7.04 (2.65), 6.98 (2.27), 6.96 (2.23),
and 6.78 (2.77), respectively. The estimated CID (95%CI) was 1.64 (1.50; 1.78) and CIR
was 29.8% (23.30%; 36.40%). Overall differences in ISS values between active drug
arms and placebowere2.82 (95%CI:3.71;1.92),3.02 (3.93;2.12), and3.87
(4.76; 2.98) for 2, 5, and 15 mg BID vs placebo, respectively; all differences were
larger (in absolute value) than the CID of 1.64, indicating that the treatment effects
were not only statistically significant but also clinically relevant. At Week 2, the
number of ISS responders was 77.78%, 68.75%, and 76.60% for 2, 5, and 15 mg BID,
respectively, vs 34.00% for placebo (p0.0001); at Week 12 the number of ISS re-
sponders increased to 91.89%, 87.18%, and 100% in the 2, 5, and 15 mg BID groups,
respectively, vs 29.41% for placebo (p0.0001). CONCLUSIONS: In patients with
psoriasis, CP-690,550 produces significant and clinically meaningful reductions in
pruritus, as measured by the patient-reported ISS.
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DISEASE SEVERITY EVALUATION AMONG DERMATOLOGICAL OUT-PATIENTS:
A COMPARISON BETWEEN THE ASSESSMENTS OF PATIENTS AND PHYSICIANS
Tabolli S, Sampogna F, Pagliarello C, Paradisi A, Spagnoli A, Abeni D
IDI IRCCS, Rome, Italy
OBJECTIVES: The assessment of a patient’s disease severity is an essential compo-
nent in the formulation of treatment strategies. This study wants to compare the
dermatological disease severity assessment by patients and by physicians, and to
describe the possible discrepancies between them.METHODS: For each patient, we
obtained the Physician Global Assessment (PhGA) and the Patient Global Assess-
ment (PtGA). Data were completed for 2.578 patients. Sixty-one physicians partic-
ipated in the study. We calculated the agreement between PtGA and PhGA scores
using the weighted kappa statistics; a multinomial logistic regression was per-
formed to assess the risk of disagreement considering both patient and physician
variables. RESULTS: Differences in the percentages of severity level, identified by
patients and by physicians, were always statistically significant (p0.05). Overall,
the weighted Cohen’s kappa was in the range of 0.09 - 0.34, depending on the
diseases. Gender differences betweenpatients andphysicians did not influence the
agreement. In the multinomial model female patients (OR1.38; 95%CI, 1.07-1.77),
patients with higher educational levels (OR2.71; 95%CI, 2.12-3.46), and patients
with impaired quality of life (OR1.56; 95%CI 1.23-1.97) had a higher risk to be
underestimated for their disease severity by physicians, independently by physi-
cian gender and experience. CONCLUSIONS: Combining the subjective report with
the objective severity assessment of the lesions, dermatologistsmay reach a better
determination of how severity of disease is perceived by their patients and how
they feel about the effectiveness of treatment. PtGA and PhGAmight be considered
in routine clinical assessments and not only for research activities.
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PSYCHOMETRIC EVALUATION OF THE NATIONAL EYE INSTITUTE VISUAL
FUNCTION QUESTIONNAIRE 25 AND VISUAL FUNCTION QUESTIONNAIRE
UTILITY INDEX IN PATIENTS WITH NON-INFECTIOUS INTERMEDIATE AND
POSTERIOR UVEITIS
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OBJECTIVES: To evaluate the psychometric properties of the National Eye Institute
Visual Function Questionnaire 25-item (NEI VFQ-25) and Visual Function Question-
naire Utilities Index (VFQ-UI) in patients with non-infectious intermediate and
posterior uveitis. METHODS: Secondary analysis of pooled data from a 26-week,
multicenter, masked, randomized, sham-controlled Phase 3 trial of dexametha-
sone intravitreal implant. Vision specific health related quality of life was assessed
using the NEI VFQ-25 at baseline and weeks 8, 16, and 26/early exit. The EQ-5D and
SF-36 were administered at baseline. Internal consistency reliability and reproduc-
ibility was measured using Cronbach’s alpha and intraclass correlation coefficient
(ICC). Validity was assessed with Spearman’s product-moment rank correlations
and known-groups of BCVA and vitreous haze severity. Clinically significant dif-
ferencewas assessed using distribution and anchor-basedmethods.RESULTS:The
study included 224 subjects with non-infectious intermediate (80.4%) or posterior
uveitis (19.6%); mean age 44.6 years; 63.4% female; 60.3% Caucasian; median vitre-
ous haze score at baseline 2.0 and median visual acuity (ETDRS) 62.5 letters (84.4%
treated in their worse seeing eye). The NEI VFQ-25 and the VFQ-UI demonstrated
good internal consistency (Cronbach’s alpha 0.87-0.94) and test-retest reliability
(ICC 0.72-0.88). Spearman’s product-moment rank correlations between the NEI
VFQ-25 andVFQ-UI scores and the SF-6D, EQ-5D, and BCVAat baseline ranged from
low to moderate. There was a significant association between visual functioning
and known groups of visual acuity, with group comparisons demonstrating signif-
icant decrease in visual functioning between 20/40 and 20/40 to 20/200
(p0.05). At week 8, clinically significant difference, based on the standard error of
measurement, was 0.04 for the VFQ-UI and ranged from 4.63 to 8.92 for the VFQ-25
domains and 3.86 for the composite score. CONCLUSIONS: The NEI VFQ-25 and the
VFQ-UI are reliable and valid measures of vision-related functioning and prefer-
ence-based status in patients with non-infectious intermediate and posterior uve-
itis.
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MEDIATION MODELING AND MEASUREMENT CHARACTERISTICS OF THE ITCH
SEVERITY SCORE FROM A PHASE 2B TRIAL OF ORAL CP-690-550 IN PATIENTS
WITH MODERATE TO-SEVERE PLAQUE PSORIASIS
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OBJECTIVES: To assess direct and indirect effects of the oral Janus kinase inhibitor
CP-690,550 on pruritus in patients with psoriasis.METHODS: In a 12-week, double-
blind, placebo-controlled Phase 2b trial, 197 patients withmoderate-to-severe pso-
riasis were randomized to CP-690,550 (2, 5 or 15 mg BID) or placebo. Pruritus was
patient-assessed using the Itch Severity Score (ISS), a 0 (‘no itching’) to 10 (‘worst
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